X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs STRIDES SHASUN LTD - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA STRIDES SHASUN LTD AUROBINDO PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 18.0 14.0 128.7% View Chart
P/BV x 5.8 1.9 309.2% View Chart
Dividend Yield % 0.4 0.6 64.4%  

Financials

 AUROBINDO PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
STRIDES SHASUN LTD
Mar-16
AUROBINDO PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,5411,413 109.1%   
Low Rs582848 68.6%   
Sales per share (Unadj.) Rs237.5353.3 67.2%  
Earnings per share (Unadj.) Rs33.923.4 144.8%  
Cash flow per share (Unadj.) Rs40.641.0 99.0%  
Dividends per share (Unadj.) Rs2.505.00 50.0%  
Dividend yield (eoy) %0.20.4 53.2%  
Book value per share (Unadj.) Rs120.6320.4 37.6%  
Shares outstanding (eoy) m585.1789.35 654.9%   
Bonus/Rights/Conversions PREFESOP-  
Price / Sales ratio x4.53.2 139.7%   
Avg P/E ratio x31.348.3 64.8%  
P/CF ratio (eoy) x26.227.6 94.8%  
Price / Book Value ratio x8.83.5 249.5%  
Dividend payout %7.421.4 34.5%   
Avg Mkt Cap Rs m621,041100,988 615.0%   
No. of employees `00013.34.7 283.3%   
Total wages/salary Rs m15,5084,988 310.9%   
Avg. sales/employee Rs Th10,457.66,730.0 155.4%   
Avg. wages/employee Rs Th1,167.11,063.6 109.7%   
Avg. net profit/employee Rs Th1,491.6445.5 334.8%   
INCOME DATA
Net Sales Rs m138,96131,564 440.3%  
Other income Rs m1,6631,212 137.2%   
Total revenues Rs m140,62432,776 429.0%   
Gross profit Rs m32,0565,213 614.9%  
Depreciation Rs m3,9261,573 249.6%   
Interest Rs m2,5681,803 142.4%   
Profit before tax Rs m27,2253,049 892.8%   
Minority Interest Rs m39127 30.9%   
Prior Period Items Rs m0-27 0.0%   
Extraordinary Inc (Exp) Rs m0-371 0.0%   
Tax Rs m7,444689 1,081.1%   
Profit after tax Rs m19,8202,089 948.6%  
Gross profit margin %23.116.5 139.7%  
Effective tax rate %27.322.6 121.1%   
Net profit margin %14.36.6 215.5%  
BALANCE SHEET DATA
Current assets Rs m100,01535,949 278.2%   
Current liabilities Rs m74,75919,402 385.3%   
Net working cap to sales %18.252.4 34.7%  
Current ratio x1.31.9 72.2%  
Inventory Days Days10771 151.4%  
Debtors Days Days110127 86.4%  
Net fixed assets Rs m52,35034,478 151.8%   
Share capital Rs m585894 65.5%   
"Free" reserves Rs m67,70722,601 299.6%   
Net worth Rs m70,56728,632 246.5%   
Long term debt Rs m8,47227,455 30.9%   
Total assets Rs m156,99476,591 205.0%  
Interest coverage x11.62.7 431.2%   
Debt to equity ratio x0.11.0 12.5%  
Sales to assets ratio x0.90.4 214.8%   
Return on assets %14.35.1 280.6%  
Return on equity %28.17.3 384.9%  
Return on capital %37.78.2 462.1%  
Exports to sales %51.048.1 106.0%   
Imports to sales %18.814.5 130.3%   
Exports (fob) Rs m70,92715,192 466.9%   
Imports (cif) Rs m26,1934,565 573.8%   
Fx inflow Rs m71,01516,612 427.5%   
Fx outflow Rs m28,7995,292 544.2%   
Net fx Rs m42,21611,320 372.9%   
CASH FLOW
From Operations Rs m17,596717 2,455.4%  
From Investments Rs m-13,801-22,284 61.9%  
From Financial Activity Rs m-19829,488 -0.7%  
Net Cashflow Rs m3,5978,073 44.6%  

Share Holding

Indian Promoters % 54.1 27.7 195.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 37.8 21.0%  
FIIs % 27.7 8.6 322.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 25.9 39.4%  
Shareholders   69,601 56,241 123.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   TTK HEALTHCARE  UNICHEM LAB  CIPLA  ELDER PHARMA  ALEMBIC LTD  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - CLARIS LIFESCIENCES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS